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Arenaviruses comprise a diverse family of rodent-borne viruses that are responsible for recurring and emerg-
ing outbreaks of viral hemorrhagic fevers worldwide. The Junín virus, a member of the New World arenavi-
ruses, is endemic to the pampas grasslands of Argentina and is the etiologic agent of Argentine hemorrhagic
fever. In this study, we have analyzed the assembly and function of the Junín virus envelope glycoproteins. The
mature envelope glycoprotein complex is proteolytically processed from the GP-C precursor polypeptide and
consists of three noncovalently associated subunits, G1, G2, and a stable 58-amino-acid signal peptide. This
tripartite organization is found both on virions of the attenuated Candid 1 strain and in cells expressing the
pathogenic MC2 strain GP-C gene. Replacement of the Junín virus GP-C signal peptide with that of human
CD4 has little effect on glycoprotein assembly while abolishing the ability of the G1-G2 complex to mediate
pH-dependent cell-cell fusion. In addition, we demonstrate that the Junín virus GP-C signal peptide subunit
is myristoylated at its N-terminal glycine. Alanine substitution for the modified glycine residue in the GP-C
signal peptide does not affect formation of the tripartite envelope glycoprotein complex but markedly reduces
its membrane fusion activity. In contrast to the classical view that signal peptides act primarily in targeting
nascent polypeptides to the endoplasmic reticulum, we suggest that the signal peptide of the arenavirus GP-C
may serve additional functions in envelope glycoprotein structure and trafficking.
Arenaviruses are the etiological agents of acute hemorrhagic
fevers with high mortality in humans. Old World arenaviruses,
such as Lassa virus and lymphocytic choriomeningitis virus
(LCMV), and New World arenaviruses, such as Junín and
Machupo viruses, are endemic to rodent populations and are
transmitted to humans through casual or aerosol contact (11,
19). Recurring and emerging outbreaks throughout the world
represent an ongoing public health problem. The potential for
use of these agents in biological warfare has elevated this
family of viruses to national concern. Here, we study the Junín
virus, a member of the New World Tacaribe complex of arena-
viruses that is responsible for recurring outbreaks of Argentine
hemorrhagic fever (AHF) in the pampas grasslands of Argen-
tina.
The arenaviruses are enveloped, bisegmented RNA viruses
(11, 19). The genome consists of two single-stranded RNA mo-
lecules, designated L (;7.2 kb) and S (;3.4 kb). The S seg-
ment encodes the major structural components of the virion:
the internal nucleocapsid protein (N) and the external enve-
lope glycoprotein precursor (GP-C). The L segment encodes
the RNA-dependent RNA polymerase (L) and a zinc-binding
matrix protein (Z). The genomic RNAs are used to produce
genomic-complementary and genomic-sense RNAs that serve
as ambisense templates for mRNA synthesis (51). Arenaviral
particles assemble at the plasma membrane and bud to pro-
duce infectious virions. Specific pathways and determinants of
virion assembly and budding remain poorly understood.
The viral envelope glycoprotein is an essential component in
the assembly and release of infectious virions and is responsi-
ble for virus entry into target cells. The arenavirus GP-C en-
velope glycoprotein precursor contains a signal peptide (SP)
sequence that targets the nascent polypeptide to the rough
endoplasmic reticulum (ER) where high-mannose glycan cores
are added at potential glycosylation sites (10, 27, 31). During
transit to the cell surface, the GP-C precursor is proteolytically
cleaved by the cellular subtilase SKI-1/S1P (4, 45) to yield the
mature glycoproteins G1 and G2. The G1-G2 complex extends
5 to 10 nm on the virion particle and is anchored to the viral
membrane by the C-terminal transmembrane domain of G2
(10) (Fig. 1).
Arenavirus entry into host cells is initiated by G1 binding to
cell surface receptors followed by endocytosis of the virion into
smooth vesicles (7). Although a-dystroglycan serves as a bind-
ing receptor for the Old World arenaviruses (13), the receptor
utilized by the major group of New World arenaviruses, in-
cluding Junín virus, is unknown (64). In the arenaviruses,
membrane fusion is pH dependent and is activated upon acid-
ification of the maturing endosome (7, 15, 21, 22). The ectodo-
main of G2 contains two heptad-repeat sequences character-
istic of coiled coils found in other viral membrane fusion
proteins including human immunodeficiency virus type 1 gp41,
influenza HA2, and Ebola virus Gp2 (33). The pH-dependent
activation and reorganization of the Junín virus envelope gly-
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coprotein complex likely involves the formation of a helical
hairpin structure in G2. Formation of the highly stable helical
bundle is thought to be directly coupled to initiation of mem-
brane fusion and entry of the infectious virion core (see refer-
ences 24, 39, and 69).
The envelope glycoprotein complex thus provides a viable
target for antiviral intervention. Passive administration of neu-
tralizing antibodies has been shown to be effective in the treat-
ment of Junín virus infection (28), but their role in Lassa fever
and LCMV infection is less clear (29). Similarly, the ability of
antiviral peptides to inhibit membrane fusion by preventing the
formation of the helix bundle structure (42, 70) suggests that a
similar therapeutic strategy may extend to the arenaviruses.
In this report, we examine the biosynthesis and assembly of
the Junín virus envelope glycoprotein complex. We show that
the 58-amino-acid residue SP of GP-C is myristoylated and
stably associated with the mature G1-G2 complex. Substitution
by the CD4 SP sequence or mutation of the myristoylation
motif dramatically reduces the ability of the envelope glyco-
protein complex to mediate pH-dependent membrane fusion.
The existence of an essential SP subunit within the envelope
glycoprotein complex points to a unique feature in the mor-
phogenesis and life cycle of arenaviruses.
MATERIALS AND METHODS
Cells, viruses, and monoclonal antibodies. The African green monkey kidney
cell line Vero 76 (CRL-1587) was obtained from the American Type Culture
Collection (Manassas, Va.) and grown in Dulbecco’s modified Eagle medium
(DMEM; Gibco) containing high glucose, sodium pyruvate, glutamine, penicil-
lin-streptomycin, and 10% fetal bovine serum (FBS). The attenuated vaccine
strain of Junín virus, Candid 1 (1, 3, 49), was kindly provided by R. Shope and R.
Tesh, World Health Organization Reference Center for Arboviruses (University
of Texas Medical Branch) and was propagated in Vero cells under biosafety level
2 conditions (16). Mouse monoclonal antibodies (MAbs) directed against the
Junín virus envelope glycoprotein were prepared against intact, gamma-irradi-
ated Junín virus particles (61) and kindly provided by A. Sanchez and T. Ksiazek
(Special Pathogens Branch, Centers for Disease Control and Prevention). The
six MAbs (GB03-BE08, GD01-AG02, QC03-BF11, EC05-AA04, LD05-BF09,
and QD04-AF03) recognize the G1 subunit (unpublished data). Plasma from
convalescent-phase AHF patients was kindly provided by Delia Enría (Instituto
Nacional de Enfermedades Virales Humanas, Pergamino, Argentina). Recom-
binant vaccinia viruses expressing the bacteriophage T7 polymerase (vTF7-3)
(32) and the b-galactosidase gene under the control of a T7 promoter (vCB21R-
lacZ) (54) were obtained from T. Fuerst and B. Moss and C. Broder, P. Kennedy,
and E. Berger, respectively, through the National Institutes of Health (NIH)
AIDS Research and Reference Reagent Program, which also provided the hu-
man CD4 cDNA (48).
Junín virus envelope glycoprotein constructs. The GP-C coding region from
the pathogenic Junín virus strain MC2 (36) was introduced into the mammalian
expression vector pcDNA 3.11 (by using an AvrII restriction site 72 bp upstream
of the GP-C initiation codon and a SmaI site 26 bp downstream of the termi-
nation codon) to yield the plasmid pcDNA-JGPC. The DNA sequence of the
MC2 GP-C gene was determined, and the corrected sequence is appended to
accession no. D10072. It should be noted that the amino acid sequence of the
MC2 GP-C gene differs from that of the attenuated Candid 1 strain by only two
conservative substitutions in G2 (I427 versus F in the transmembrane domain
and S446 versus T in the cytoplasmic domain of MC2) and that the basis for
attenuation in the Candid 1 strain is unknown (1, 35). An adventitious polyad-
enylation motif (AATAAA) in the MC2 GP-C open reading frame was mutated
(GATCAA) without changing the encoded amino acids to obviate potential
problems in expression. A 15-amino-acid residue S-peptide (Spep) affinity tag
(KETAAAKFERQHMDS) (43) was introduced at the C-terminal cytoplasmic
end of GP-C (pcDNA-JGPC/Spep) to facilitate biochemical analysis (34). A
mutation to generate an SKI-1/S1P cleavage-defective GP-C gene (RRSLK to
AASLK) (4, 44) (cd JGPC/Spep) was introduced by QuikChange mutagenesis
(Stratagene). The SP of human CD4 (48) was adapted by PCR and used to
replace the Junín virus GP-C SP sequence in the CD4sp-JGPC construct. DNA
FIG. 1. Schematic representation of the Junín virus GP-C glycoprotein and SP. (A) The Junín virus MC2 GP-C glycoprotein is depicted. Amino
acids are numbered from the initiating methionine, and cysteine residues (|) and potential glycosylation sites (Y) are marked. The SP cleavage
site (after amino acid 58) and the SKI-1/S1P cleavage site (after amino acid 251) and the resulting SP, G1 and G2 subunits are indicated. Within
G2, the C-terminal transmembrane domain (TM) is shown, as are heptad-repeat regions (light gray shading) that may be involved in membrane
fusion. The N termini of the arenavirus G1 and G2 glycoproteins have been previously determined experimentally (10, 12, 27, 45). (B) A
comparison of the signal peptides of New World (Junín MC2 [accession no. D10072], Tacaribe [accession no. M20304], Pichinde´ [accession no.
M16735], Machupo [accession no. AY129248], and Sabia´ [accession no. U41071]) and Old World (Lassa-Nigeria [Lassa-N, accession no. X52400],
Lassa-Josiah [Lassa-J, accession no. M15076], Mopeia [accession no. M33879], LCMV-Armstrong [LCMV-A, accession no. M20869] and
LCMV-WE [accession no. M22138]) arenaviruses is shown. Identically conserved regions are highlighted, as is the conserved myristoylation (myr)
motif G-X3-S/T (59).
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sequencing was used to confirm all manipulations, and three independent clones
of each were originally evaluated to assure a consistent phenotype.
Expression and analysis of Junín virus envelope glycoproteins. The attenu-
ated Junín virus, Candid 1, was grown in Vero cells and quantitated by focus
formation after 4 days of growth under agarose overlay. Foci of infected cells
were identified by indirect immunostaining of cold methanol-acetone (1:1)-fixed
monolayers by using AHF plasma or mouse MAbs directed to G1 (61), horse-
radish peroxidase-conjugated secondary antibodies, and diaminobenzidine sub-
strate. The Junín virus GP-C envelope glycoprotein was transiently expressed in
Vero cells by using either FuGene-6 (Roche Biochemicals) or Metafectene
(Biontex, Munich, Germany) reagent for transfection as described by the respec-
tive manufacturers. Optimal expression of the Junín virus GP-C gene was
achieved by using the T7 promoter of the pcDNA vector and a recombinant
vaccinia virus expressing the T7 polymerase (vTF7-3) (32). In these studies, Vero
cells in 10-cm-diameter culture dishes were infected with vTF7-3 for 30 min at a
multiplicity of infection of 2 in DMEM containing 2% FBS and 10 mM cytosine
arabinoside (araC) to limit vaccinia virus DNA replication and cytopathic effect
(41). Cultures were then transfected with plasmid DNA and continued in me-
dium containing 10% FBS and araC. Expression was detected by immunostain-
ing after 24 h as described above. For metabolic labeling, cultures were grown for
6 h following transfection and subsequently labeled for 18 h with 125 mCi (each)
of [35S]methionine and [35S]cysteine (Amersham Biosciences) in cysteine- and
methionine-free DMEM. Cultures infected with Candid 1 virus were labeled for
18 h starting 5 days after infection with a multiplicity of approximately 0.5
focus-forming units per cell. In some studies, cultures were labeled with 250 mCi
of [3H]myristic acid (Amersham Biosciences) in DMEM containing 5 mM so-
dium pyruvate and delipidated FBS (Cocalico Biologicals, Inc.).
Metabolically labeled cultures were washed in physiologic buffered saline
(PBS), and cells were subsequently lysed with cold buffer containing 50 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, and protease inhibitors (1
mg [each] of aprotinin, leupeptin, and pepstatin/ml). A soluble fraction was
prepared by centrifugation at 15,000 3 g for 30 min at 4°C. Cell culture super-
natants were filtered (0.2-mm pore size) and chilled prior to the addition of
Triton X-100 to 1%. Immunoprecipitation with convalescent-phase AHF plasma
or G1-specific MAbs was performed at 4°C for 1 h in lysis buffer, and immune
complexes were isolated with protein A-Sepharose (Sigma). Spep-tagged glyco-
proteins were precipitated at 4°C for 12 h with S-protein agarose beads (SAG;
Novagen). For all precipitations, cell and viral lysates were precleared with
protein A-Sepharose or bovine serum albumin-conjugated agarose beads
(Sigma), respectively. In some studies, the isolated glycoproteins were subse-
quently deglycosylated with peptide N-glycosidase F (PNGase F; New England
Biolabs) as described by the manufacturer (73).
Isolated proteins were analyzed by Laemmli sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis (SDS-PAGE), generally following the reduction of
disulfide linkages by boiling in 100 mM dithiothreitol. In some studies, commer-
cial NuPAGE Bis-Tris gels were used (Invitrogen). 35S-labeled proteins were
visualized by phosphorimaging with a Fuji FLA-3000G instrument. Tritium-
labeled proteins were detected by fluorography following treatment with Amplify
(Amersham Biosciences). Spep-tagged proteins were detected by Western blot
analysis with S-protein-conjugated horseradish peroxidase (Novagen).
Analysis of cell-cell fusion. Cell-cell fusion mediated by the Junín virus enve-
lope glycoprotein was assessed in Vero cells by the formation of multinucleated
syncytia and by the b-galactosidase fusion reporter gene assay (54). In the
syncytium-formation assay, vTF7-3-infected cell cultures expressing the Junín
virus envelope glycoproteins were grown on poly-D-lysine-coated plates for 24 h
in the presence of araC as described above. Cells were pulsed for 1 h with neutral
pH medium or with medium adjusted to pH 5.0 [DMEM containing 10 mM
HEPES, 10 mM piperazine-N,N9-bis(2-ethanesulfonic acid) (PIPES), and 10 mM
araC]. Previous studies had identified pH 5.0 as optimal for cell-cell fusion of
Junín virus-infected cells (14). Cultures were then continued for 2 h in neutral
growth medium containing araC and subsequently fixed with cold methanol-
acetone (1:1). Junín virus envelope glycoprotein-expressing cells and syncytia
were detected by immunostaining as described above. In the b-galactosidase
fusion reporter gene assay, Vero cells infected with a recombinant vaccinia virus
bearing the b-galactosidase gene under the control of a T7 promoter (vCB21R-
lacZ) served as the target for JGPC-mediated cell-cell fusion (54). In this assay,
cultures were infected with vCB21R-lacZ for 90 min at a multiplicity of infection
of 2 in DMEM containing 2% FBS. Cells were then washed and used to seed
96-well poly-D-lysine-coated microculture dishes (15,000 cells/well) in DMEM
containing 10% FBS and 100 mg of rifampin (Sigma)/ml to minimize vaccinia
virus assembly and cytopathic effect (41). After overnight incubation, parallel
cultures of vTF7-3-infected and JGPC-expressing cells were harvested in PBS
containing 0.1 mM EDTA, resuspended in growth medium containing 2% FBS,
10 mM araC, and 100 mg of rifampin/ml, and 15,000 cells were added to each
microculture containing the vCB21R-lacZ-infected target cells. After 4 h, the
cocultures were pulsed for 1 h with neutral or pH 5.0 medium containing araC
and rifampin and were subsequently refed with neutral medium (containing araC
and rifampin), and culture continued for 5 h. At this time, cultures were washed
and fixed for 5 min at 4°C in PBS containing 2% formaldehyde and 0.2%
glutaraldehyde (54). Staining for b-galactosidase activity was in PBS containing
5 mM (each) potassium ferricyanide and potassium ferrocyanide, 2 mM MgCl2,
and 1 mg of 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal; Sigma)/
ml. In other experiments, cocultures were solubilized with lysing solution
(Tropix) and the expressed b-galactosidase was quantitated by using the chemi-
luminescent substrate Galacto-Lite plus (Tropix) as recommended by the man-
ufacturer. Chemiluminescence was determined by using a Tropix TR717 micro-
plate luminometer.
Sequence analysis. Sequence comparisons among arenavirus GP-C proteins
used the NIH BLAST server at http://www.ncbi.nlm.nih.gov/BLAST. Predictive
analyses of protein sequences utilized the PredictProtein suite of programs (60).
SP sequences were analyzed by using the SignalP algorithms (versions 1.1 and
2.0) (52, 53) available at http://www.cbs.dtu.dk/services/SignalP/. Myristoylation
motifs were identified by using ProSite at http://www.expasy.ch/prosite/ (40) and
were further evaluated by using the MYRbase server at http://mendel.imp.univie
.ac.at/myristate (50).
RESULTS
pH-dependent membrane fusion by the Junín virus envelope
glycoprotein. Entry of the arenavirus into the target cell is
mediated by conformational changes in the envelope glycopro-
tein complex induced upon acidification of the endosome (7,
15, 21, 22). Membrane fusion can also be induced by the
envelope glycoprotein on the surface of infected cells by ex-
posing the cultures to acidic pH (14). To examine the fusogenic
properties of the Junín virus GP-C, Vero cell cultures express-
ing the molecularly cloned GP-C gene of the pathogenic MC2
isolate of Junín virus (JGPC) were pulsed with medium ad-
justed to pH 5.0 (14). As shown in Fig. 2A, cell-cell fusion of
JGPC-expressing cells to form multinucleated syncytia was
only observed upon low pH treatment. The ability to generate
syncytia was unaffected by the addition of the C-terminal af-
finity tag in JGPC/Spep. In contrast, mutation of the SKI-1/S1P
recognition site to prevent G1-G2 cleavage (4, 44) abolished
pH-dependent cell-cell fusion (cd JGPC/Spep).
Fusion activity was also assessed by using the b-galactosidase
reporter gene assay (54). In this format, Vero cells expressing
JGPC under the control of the T7 RNA polymerase produced
by vTF7-3 were cocultured with cells infected by the recombi-
nant vaccinia virus vCB21R-lacZ containing the LacZ gene
under the control of the T7 promoter (54). Cell-cell fusion
enables expression of b-galactosidase, which is visualized by
X-Gal staining (Fig. 2B) or quantitated by using a chemilumi-
nescent b-galactosidase substrate (see Fig. 5). The results ob-
tained with this reporter assay were concordant with those
deduced from syncytium formation. Taken together, these as-
says demonstrate that the wild-type and Spep-tagged Junín
virus GP-C genes expressed in Vero cells are competent to
promote pH-dependent cell-cell fusion. Elimination of the
SKI-1/S1P proteolytic cleavage site abolishes fusogenicity.
Expression of Junín virus envelope glycoprotein. To deter-
mine the basis for membrane fusion by the Junín virus enve-
lope glycoproteins, we examined the envelope glycoprotein
complex in cells infected with the attenuated vaccine strain of
Junín virus, Candid 1 (1, 3, 49), and in cells expressing the
JGPC plasmid constructs. Cells were metabolically labeled
with [35S]methionine and [35S]cysteine, and the expression of
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the GP-C glycoproteins was examined in nonionic detergent
lysates of cells and in the cell culture supernatant.
The immunoprecipitation of Candid 1-infected cells with
MAb AF03 directed to G1 resulted in the isolation of a band
of 35 kDa and a more heterogeneous species of 30 to 35 kDa
(Fig. 3A, lane 1), consistent with one or both of the viral
glycoproteins G1 and G2. In addition, a 60-kDa glycoprotein
representing the uncleaved G1-G2 precursor (GP-C) was also
detected. In the culture supernatant of Candid 1-infected cells
(Fig. 3B, lane 1), virion particles contained a predominant
smear of the 30- to 35-kDa glycoprotein(s). The unprocessed
GP-C precursor was largely excluded from packaging in the
virion particle (see also reference 44).
Further definition of the viral glycoproteins was obtained by
deglycosylation with PNGase F. In this analysis (Fig. 3C and D,
lanes 1), the expected 25- and 28-kDa polypeptides of G1 and
G2, respectively, were readily distinguished and both G1 and
G2 glycoproteins were present in infected cells and on virion
particles. The finding that G2 could be precipitated by using
MAbs directed to G1 indicated that the subunits remain asso-
ciated upon solubilization of the virion in nonionic detergent.
SDS-PAGE analysis of the glycoprotein complex under non-
reducing conditions demonstrated that the association be-
tween heterologous G1 and G2 subunits and among homolo-
gous subunits is through noncovalent interactions (data not
shown).
Examination of the immunoprecipitated glycoproteins also
reveals a small polypeptide of approximately 5 kDa in the
G1-G2 complex isolated from infected cells and virion particles
(Fig. 3A and B, lanes 1). A similarly sized polypeptide has been
characterized as a stable form of the GP-C SP in cells express-
ing the Lassa virus GP-C (27) and in LCMV virions (31).
Nonetheless, the inclusion of the SP within the Candid 1 virion
and, importantly, in association with the G1-G2 complex was
unexpected. As judged by SDS-PAGE under nonreducing con-
ditions, the stable SP (SSP) is noncovalently associated with
the G1-G2 complex (see below).
The pattern of GP-C expression in JGPC- and JGPC/Spep-
transfected cells was fundamentally similar to that in Candid
1-infected cells, except for the appearance of a 65-kDa form of
GP-C precursor in the transfected cells (Fig. 3A and C, lanes
3 and 4). The 60-kDa precursor found in virus-infected cells
FIG. 2. pH-dependent fusion mediated by Junín virus envelope glycoproteins. Vero cells expressing either the unmodified Junín virus GP-C
glycoprotein (JGPC), the Spep-tagged JGPC/Spep, or the SKI-1/S1P cleavage defective mutant cd JGPC/Spep were tested for their ability to
mediate cell-cell fusion. In panel A, cultures of expressing cells were pulsed with medium at pH 5.0 or with neutral medium for 1 h and then
incubated for 2 h prior to fixation with cold methanol-acetone (1:1). Cells infected with the T7 polymerase-expressing vaccinia virus vTF7-3 but
not transfected with envelope glycoprotein plasmid (vaccinia only) served as negative controls. Cultures were stained with anti-G1 MAb AF03, a
secondary antibody conjugated to horseradish peroxidase and diaminobenzidine substrate. Multinucleated syncytia were visualized microscopically.
In panel B, parallel assays were performed by using the b-galactosidase fusion reporter gene assay (54). Here, envelope glycoprotein-expressing
cells were cocultured with Vero cells infected with a recombinant vaccinia virus bearing the b-galactosidase gene under the control of the T7
promoter (vCB21R-lacZ). Cocultures were then pulsed with medium at pH 5.0 or neutral pH and continued for 5 h. Following fixation with
formaldehyde-glutaraldehyde, cell-cell fusion and b-galactosidase expression were detected with X-Gal substrate. Cocultures of cells infected with
the respective vaccinia viruses but without an envelope glycoprotein plasmid (vaccinia only) served as negative controls.
10786 YORK ET AL. J. VIROL.







was also present. We, as others (27, 31), suggest that the larger
precursor represents the entire GP-C glycoprotein, with the
58-amino-acid SP uncleaved. The significant levels of the two
precursor glycoproteins in transfected cells, relative to that in
Candid 1-infected cells, is likely due to the saturation of the
cell’s proteolytic pathways upon overexpression (5). Despite
the abundance of the 65-kDa full-length GP-C precursor, we
found no evidence of a 35- to 40-kDa precursor containing only
the SP and G1, suggesting that the SP and SKI-1/S1P cleavages
are ordered during biosynthesis and that cleavage of the
former is essential for subsequent maturation by SKI-1/S1P
(see also reference 27). By contrast, the SP cleavage event was
unaffected by the defect at the SKI-1/S1P cleavage site in cd
JGPC-Spep (Fig. 3A and C, lanes 5). The identification of the
28-kDa deglycosylated polypeptide as G2 was further validated
by the higher molecular size of the Spep-tagged G2 polypep-
tide from JGPC/Spep (Fig. 3C, lanes 3 versus 4) and by West-
ern blot analysis with S-protein-conjugated horseradish perox-
idase (data not shown).
Importantly, the mature glycoproteins G1 and G2 were gen-
erated in JGPC- and JGPC/Spep-expressing cells, as was the
5-kDa SSP. Moreover, the three subunits were all coprecipi-
tated by using either the anti-G1 MAb (Fig. 3A and C) or SAG
(data not shown). Coprecipitation was observed upon lysis in
our standard 1% Triton X-100 nonionic detergent as well as in
mixtures with 60 mM b-octyl glucoside (data not shown); the
latter is a nonionic detergent known to efficiently extract gly-
coproteins from Triton-resistant membranes (8). Thus, the as-
sociation among subunits is not dependent upon colocalization
in detergent-resistant membrane fragments but appears to be
mediated by protein-protein interactions.
The growth medium of cultures expressing either JGPC or
JGPC/Spep contained G1 but not G2 (Fig. 3B and D, lanes 3
and 4). This suggests that the arenavirus envelope glycopro-
teins alone are not sufficient to mediate budding and the re-
lease of membrane-bound particles. The G1 found in the me-
dium is likely released by shedding from the noncovalently
associated G1-G2 complex on the cell surface. As expected,
neither G1 nor G2 was found upon expression of the cd JGPC/
Spep plasmid nor was the 5-kDa polypeptide released to the
medium (Fig. 3B, lanes 3 and 4). This suggests that the SP
remains associated with the cell and virion membranes, pre-
sumably via the hydrophobic region, as a signal anchor.
Taken together, this analysis suggests that the Junín virus
envelope glycoproteins assemble as a tripartite complex of the
SSP, G1, and G2 subunits. Proteolytic cleavage of SSP from
the GP-C precursor may in fact be mediated by the cellu-
lar signal peptidase. The SignalP algorithm (version 1.1) (52),
trained to recognize signal sequences and signal peptidase
cleavage sites, is able to identify the authentic cleavage site
(SCT-EE), albeit among several potential cleavage sites (data
not shown). A recent SignalP algorithm utilizing a hidden
Markov model (version 2) (53) is, however, unable to deter-
mine a nominal signal peptidase cleavage site in the Junín virus
GP-C sequence (data not shown). Although typical SP n and h
(hydrophobic) regions (52) are detected in SSP with modest
scores by this latter algorithm (0.35 versus 1.0 in the well-
characterized CD4 signal sequence), a canonical c region and
cleavage motif was not found (cleavage probability, 0.025).
Thus, the SSP region likely serves to target the nascent
polypeptide to the ER membrane, but the biogenesis and func-
tion of this unusual signal sequence is unclear.
Role of SSP in envelope glycoprotein assembly and function.
To determine whether the SSP functions solely as a signal
sequence, we replaced SSP in JGPC/Spep with the 25-amino-
acid SP of human CD4. Upon expression in Vero cells, the
chimeric CD4sp-JGPC/Spep precursor glycoprotein was syn-
thesized and proteolytically processed to yield G1 and G2
similarly to the native JGPC/Spep glycoprotein. SDS-PAGE
analysis of the expressed glycoproteins is illustrated in Fig. 4
following deglycosylation with PNGase F. The efficiency of
FIG. 3. Expression and biogenesis of the Junín virus GP-C. Vero
cells infected with Candid 1 virus or expressing recombinant forms
of the GP-C were metabolically labeled with [35S]methionine and
[35S]cysteine, and the envelope glycoproteins were immunoprecipi-
tated with the anti-G1 MAb AF03. Panels A and B represent envelope
glycoproteins from cell lysates and cell culture supernatants, respec-
tively. Panels C and D represent the same samples, respectively,
treated with PNGase F to generate the deglycosylated polypeptides.
Recombinant forms of the envelope glycoprotein gene are unmodified
Junín virus GP-C (JGPC), the Spep-tagged JGPC/Spep, and the SKI-
1/S1P cleavage defective mutant cd JGPC/Spep. Mock-transfected
cells are also represented. Lanes are numbered, and specific compar-
isons among samples are discussed in detail in the text. The 14C-
labeled-protein markers (Amersham Biosciences) are indicated in
kilodaltons and shown by dots. The positions of the GP-C precursors
and G2, G1, and SSP subunits are labeled. SSP bands in PNGase
F-treated samples are distorted by nonionic detergent. In panel D
(left), the source of the diffuse bands (below the G1 polypeptide and
at '16 kDa) is unclear.
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proteolytic maturation appeared somewhat altered in the CD4sp
chimera relative to the native JGPC/Spep glycoprotein (Fig. 4,
lanes 1 and 2), but the G1-G2 complex remained associated in
the chimera and could be precipitated by either anti-G1 MAbs
(Fig. 4, lanes 1 and 2) or SAG (data not shown). As judged by
the extent of G1 shedding (Fig. 4, lanes 3 and 4), the transport
and integrity of the G1-G2 complex was unaffected by substi-
tution of the CD4 SP.
These data suggest that the SSP subunit of the Junín virus
GP-C is not required for the biogenesis of the G1-G2 complex.
Therefore, we were surprised to find that the G1-G2 complex
produced in conjunction with the CD4 SP was entirely unable
to mediate membrane fusion (CD4sp-JGPC/Spep) (Fig. 5).
This finding suggests that SSP plays an integral role in the
function of the envelope glycoprotein complex.
SSP subunit is myristoylated. The potential involvement of
the SSP in envelope glycoprotein function was further sug-
gested by the presence of a canonical myristoylation motif
(G-X3-S/T) (59) at the amino terminus. This motif is conserved
among all of the arenavirus SSP sequences (Fig. 1) and sug-
gested to us that myristoylation may be an important compo-
nent in the biosynthesis and assembly of the arenavirus enve-
lope glycoprotein complex. Fatty acid addition is a widely
recognized form of protein modification that is often associ-
ated with regulatory and membrane trafficking roles (reviewed
in reference 59). To determine whether the Junín virus SSP
subunit was myristoylated, JGPC/Spep-expressing cells were
metabolically labeled with [3H]myristic acid. Upon immuno-
precipitation with a G1-specific MAb, the 5-kDa SSP subunit
was clearly detected by fluorography (Fig. 6). Neither G1 nor
G2, or either of the GP-C precursors, was labeled with the
[3H]myristic acid. Thus, the conserved myristoylation motif in
FIG. 4. Analysis of expression of GP-C bearing CD4 SP. GP-C
constructs were expressed in Vero cells and metabolically labeled with
[35S]methionine and [35S]cysteine. In the CD4sp-JGPC/Spep con-
struct, the GP-C SP has been replaced with that of CD4. The glyco-
proteins were immunoprecipitated from cell lysates (cells, left panel)
or cell culture supernatants (supt, right panel) with the anti-G1 MAb
BF11. All isolated glycoproteins were subsequently deglycosylated with
PNGase F to better resolve the G1 and G2 polypeptides. Markers and
labels are as described in the legend to Fig. 3.
FIG. 5. Quantitative analysis of cell-cell fusion by mutant Junín
virus envelope glycoproteins. Vero cells infected with vTF7-3 and
expressing the Junín virus envelope glycoproteins and cells infected
with vCB21R-lacZ were cocultured as described for the b-galactosi-
dase fusion reporter gene assay (see legend to Fig. 2B). b-Galactosi-
dase expression was quantitated by chemiluminescence with Galacto-
Lite Plus (Tropix) substrate and is presented in relative light units.
Cultures pulsed with medium at pH 5.0 are indicated by dark grey bars,
and cultures treated at neutral pH are indicated by light grey bars.
Cocultures of cells infected with the respective vaccinia viruses but
without the GP-C expression plasmid are shown with the label vLacZ1
vT7. Standard deviations among replicate cocultures are shown. The
extent of pH-dependent cell-cell fusion is determined after subtracting
the relative light unit value of the culture treated at neutral pH.
FIG. 6. Myristoylation of the Junín virus SSP. Vero cells expressing
JGPC/Spep were metabolically labeled with either [35S]methionine and
[35S]cysteine or [3H]myristic acid as described in Materials and Methods.
Cell lysates were immunoprecipitated with anti-G1 MAb BF11 and ana-
lyzed by SDS-PAGE. In this experiment, protein samples were not re-
duced prior to electrophoresis.
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SSP is utilized in the Junín virus envelope glycoprotein. Fur-
thermore, the 5-kDa myristoylated SSP was detected regard-
less of whether the immunoprecipitated complex had been
reduced prior to SDS-PAGE (data not shown), indicating that
SSP is not disulfide linked to G1 or G2.
Role of myristoylation in envelope glycoprotein biogenesis
and function. To investigate the specific role of myristoylation
of the SSP subunit, we replaced the critical glycine of the
G-X3-S/T motif with alanine. This relatively conservative sub-
stitution at the N-terminal glycine (following the initiating me-
thionine) has been shown in a number of studies to specifically
prevent myristoylation and affect membrane association. The
G2A mutation was thus introduced into JGPC/Spep to assess
the effects on envelope glycoprotein biogenesis and function.
As shown in Fig. 7A, we could detect no differences in the
biosynthesis, proteolytic maturation, assembly, or shedding of
the G2A JGPC/Spep glycoproteins relative to the wild type.
Importantly, the G2A SSP subunit was coprecipitated with G1
and G2 by using the anti-G1 MAb BF11 (Fig. 7A, lanes 3 and
4). Metabolic labeling of the G2A mutant SSP with [3H]myr-
istic acid confirmed the lack of myristoylation and also the
location and identity of the 3H-fatty acid in the wild-type SSP
(data not shown). Despite the lack of myristoylation, the G2A
SSP was not detected in the cell culture medium, suggesting
that the SP sequence was sufficient to maintain membrane
anchorage. Therefore, myristoylation per se did not appear to
grossly affect the assembly or transport of the SSP-G1-G2
envelope glycoprotein complex.
By contrast, the G2A mutant of JGPC was markedly defec-
tive in mediating cell-cell fusion. In the quantitative b-galac-
tosidase reporter gene assay (Fig. 5), cell-cell fusion by the
G2A mutant was reduced to 25% of the wild-type level.
Whereas this finding is consistent with that obtained with the
CD4 SP construct CD4sp-JGPC/Spep, the G2A mutant spe-
cifically demonstrates that myristoylation of the SSP subunit is
necessary for membrane fusion. Apparently, the nonmyristoy-
lated SSP is able to associate with the G1-G2 complex but in a
manner that is unable to support efficient envelope glycopro-
tein complex-mediated fusion.
DISCUSSION
This study demonstrates that the 58-amino-acid SP of the
Junín virus GP-C envelope glycoprotein precursor is myristoy-
lated and integrally involved in the structure and function of
the envelope glycoprotein. We show that the mature envelope
glycoprotein complex comprises three subunits derived from
GP-C by two ordered proteolytic cleavage events. The initial
cleavage results in the generation of the N-terminal 58-amino-
acid polypeptide containing a hydrophobic core region that
acts as a signal sequence (see also references 25and 31). In
contrast to conventional SPs, however, the GP-C SP is stable
and is found associated with G1 and G2 on the mature Junín
virion. Moreover, this polypeptide is specifically acylated at an
N-terminal myristoylation motif that is conserved in all arena-
viral GP-C glycoproteins. The protease responsible for the SSP
cleavage event is uncertain, but some predictive algorithms
suggest that the cellular signal peptidase may be involved. The
second cleavage event is mediated by the cellular SKI-1/S1P
subtilase (4, 45). This cleavage generates the two conventional
envelope glycoprotein subunits: the receptor-binding G1 moi-
ety and the transmembrane G2 protein. Our results indicate
that this latter cleavage is independent of the SSP per se but
does require a functional SP such as that provided by CD4.
These ordered cleavage events likely occur during progress of
the nascent envelope glycoprotein complex along the ER and
Golgi membranes.
The cleaved SSP, G1, and G2 remain noncovalently associ-
ated on the mature virion. This tripartite organization of the
envelope glycoprotein complex is distinct from that in many
other viruses. Although the incorporation of small virion mem-
brane polypeptides within viral envelopes is not unprecedented
(for examples, see references 47 and 72), the topology of the
SSP subunit and the organization of the Junín virus envelope
glycoprotein complex are largely unknown (see references 26,
31). In the native complex, the hydrophobic core of the SSP
subunit may act in part as a signal anchor to mediate mem-
brane attachment. This function may be enhanced by myris-
toylation of the SSP N terminus. It is also possible that SSP
interacts with transmembrane region of G2.
Although neither the SSP subunit nor the myristoylation
event is essential for assembly and transport of the G1-G2
complex, the myristoylated SSP subunit is required for the
mature envelope glycoprotein complex to mediate pH-depen-
dent membrane fusion. Interestingly, a functional SSP of the
cd JGPC complex can act in trans to rescue fusion activity of
the CD4sp-JGPC complex (unpublished data; see also ref-
erence 25). Furthermore, a mutant envelope glycoprotein
FIG. 7. Analysis of expression of the nonmyristoylated G2A mu-
tant of GP-C. Wild-type JGPC/Spep and the G2A myristoylation site
mutant G2A-JGPC/Spep were expressed in Vero cells and metaboli-
cally labeled with [35S]methionine and [35S]cysteine. (A) Glycoproteins
from cell culture supernatants (supt) or cell lysates (cells) were ana-
lyzed following immunoprecipitation with the anti-G1 MAb BF11 by
PAGE with a 10% Bis–Tris NuPAGE gel and morpholineethanesul-
fonic acid (MES) running buffer. A sample from a mock-transfected
culture is shown to identify nonspecific background bands. (B) The im-
munoprecipitated glycoproteins from cell lysates were deglycosylated
with PNGase F prior to electrophoresis. Markers and labels are as
described in the legend to Fig. 3.
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containing a G2A mutation that prevents myristoylation is
markedly defective in promoting cell-cell fusion. Thus, the
myristoylated SSP subunit appears to not be required for mem-
brane association per se but rather for the ultimate fusion
activity of the mature complex. This finding is unexpected
because protein acylation often acts to modulate membrane
association (reference 59 and references therein). For in-
stance, myristoylation of the retrovirus matrix protein is essen-
tial for the stable association of the Gag precursor with cellular
membranes and, thus, for assembly of the virion core (9, 37, 38,
56). The role of acylation is more complex for transmembrane
viral envelope glycoproteins. Mutations that prevent palmitoyl-
ation of the envelope glycoproteins of orthomyxoviruses (74)
and retroviruses (23, 30, 55, 63) interfere with virion assembly,
although the nonacylated forms of these glycoproteins appear
to retain their intrinsic ability to mediate membrane fusion (65,
71).
The precise role of the myristoylated SSP in the Junín virus
envelope glycoprotein complex is not known. It is possible that
the myristic acid moiety of the SSP serves an integral structural
role, as it does in picornavirus assembly (2, 18). The SSP
polypeptide may itself be important in maintaining envelope
glycoprotein structure to enable proper assembly and/or func-
tion of the complex. One may imagine a role in stabilizing the
prefusogenic form of the envelope glycoprotein. Because virus-
mediated membrane fusion is a cooperative process involving
multiple envelope glycoprotein oligomers in the stabilization
of the fusion pore (6, 46), higher-order interactions among SSP
subunits may also be involved.
The myristoylated SSP may also be involved in modulating
membrane fusion through effects on membrane trafficking of
the envelope glycoprotein complex. In particular, cellular
membranes are not homogeneous but rather contain special-
ized regions called rafts that are enriched in cholesterol and
sphingolipids and form ordered microdomains that function as
platforms for protein-protein interactions and for macromo-
lecular assembly (see references 62 and 67 and references
therein). Recent studies highlight the critical role of rafts in
the assembly, budding, and infectivity of diverse viruses (see
references 17, 58, and 68 and references therein), and it is
possible that myristoylation of the SSP may be important in di-
recting the Junín virus envelope glycoprotein complex to mem-
brane rafts. In the case of the influenza virus hemagglutinin,
the increased local concentration of envelope glycoprotein
within rafts has been shown to facilitate the highly cooperative
process of membrane fusion (68). The defect in membrane
fusion by the nonmyristoylated Junín virus envelope glycopro-
tein may likewise derive from a failure to concentrate in mem-
brane rafts. Further studies are needed to determine whether
or not the Junín virus envelope glycoproteins are associated
with membrane rafts. Because raft-associated glycoproteins
typically distribute between raft and nonraft membranes, it is
not inconsistent for us to find the Junín virus envelope glyco-
proteins in the detergent-soluble (i.e., nonraft) cell fraction
examined in the present work.
The importance of myristoylation determined in our genetic
studies is consistent with the reported sensitivity of the Junín
virus to analogs of myristic acid (20). In the previous study, the
expression of the Junín virus envelope glycoproteins was not
affected by the analogs, although the basis for the defect in
infectivity—in virion assembly, budding, or entry—was not ad-
dressed. It should be noted, however, that the arenavirus Z (or
matrix) (57, 66) protein contains an N-terminal myristoylation
motif that may or may not be utilized, and therefore, the pre-
cise target of myristic acid analogues is unclear. It is possible
that the arenaviruses utilize myristoylation to colocalize the
envelope glycoproteins and the virion matrix protein for virion
assembly. Further analysis of arenavirus assembly and enve-
lope glycoprotein function may point to specific targets for an-
tiviral intervention. The development of safe and effective vac-
cines and therapeutics to combat arenaviral hemorrhagic fever
will have broad implications for public health and biodefense.
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